FindTrial
Sign In

GVAX

BIOLOGICAL10 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana-Farber Cancer Institute, Massachusetts General Hospital

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaColorectal CancerLocally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)MelanomaMetastatic Colorectal CancerMultiple MyelomaMyelodysplastic Syndrome

Phase 1

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
CompletedNCT00024466
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMultiple Myeloma
Start: 2001-04-30End: 2009-04-30Updated: 2018-09-19
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
CompletedNCT00258687
Dana-Farber Cancer InstituteMelanoma, Renal Cell Carcinoma, Sarcoma, Alveolar Soft Part +1
Start: 2005-01-31End: 2020-12-31Updated: 2021-03-03
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
CompletedNCT01696877
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer Adenocarcinoma in Situ
Start: 2013-01-18End: 2018-12-18Updated: 2019-03-28
Pilot Study of GVAX in Colorectal Cancer Cells
TerminatedNCT01952730
Massachusetts General HospitalColorectal Cancer
Start: 2013-11-08End: 2020-02-29Updated: 2023-01-12
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
CompletedNCT01966289
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Colorectal Cancer
Start: 2014-04-14End: 2020-06-06Updated: 2021-03-30
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
CompletedNCT03767582
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLocally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Start: 2019-12-12End: 2025-02-01Updated: 2025-12-03
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
RecruitingNCT06782932
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer
Start: 2025-05-27End: 2028-12-31Target: 38Updated: 2025-12-03

Phase 2

GVAX vs. Placebo for MDS/AML After Allo HSCT
TerminatedNCT01773395
Dana-Farber Cancer InstituteAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Start: 2013-01-08End: 2021-11-24Updated: 2022-07-18
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
CompletedNCT02243371
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPreviously Treated Metastatic Adenocarcinoma of the Pancreas
Start: 2015-01-02End: 2017-07-21Updated: 2021-04-06
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
CompletedNCT02981524
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Colorectal Cancer
Start: 2017-05-26End: 2018-03-20Updated: 2021-02-10

Related Papers

Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
Journal of Clinical Oncology2023-01-2421 citations
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
Blood Advances2021-11-2220 citations
A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
Clinical Epigenetics2021-02-0228 citations
Human prostate cancer immune phenotypes after androgen deprivation therapy.
Journal of Clinical Oncology2019-05-201 citations
A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer.
Journal of Clinical Oncology2019-01-297 citations
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
2018-07-12191 citations
Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).
Journal of Clinical Oncology2017-05-2014 citations
Randomized phase 2 study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2016-05-203 citations
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2016-02-0113 citations
Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).
Journal of Clinical Oncology2015-05-209 citations